Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation

Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients that are undergoing chemotherapies. However, earlier research on the relationship between BMI and survival in patients taking epidermal growth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Mu Chen, Chien-Hao Lai, Chiung-Yu Lin, Yi-Hsuan Tsai, Ya-Chun Chang, Hung-Chen Chen, Chia-Cheng Tseng, Huang-Chih Chang, Kuo-Tung Huang, Yung-Che Chen, Wen-Feng Fang, Chin-Chou Wang, Tung-Ying Chao, Meng-Chih Lin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	body mass index weight loss non-small cell lung cancer tyrosine kinase inhibitor Nutrition. Foods and food supply TX341-641
Acceso en línea:	https://doaj.org/article/f6b4a7988ca7414f8acc45de727e6885
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6b4a7988ca7414f8acc45de727e6885
record_format	dspace
spelling	oai:doaj.org-article:f6b4a7988ca7414f8acc45de727e68852021-11-25T18:33:50ZBody Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation10.3390/nu131137612072-6643https://doaj.org/article/f6b4a7988ca7414f8acc45de727e68852021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6643/13/11/3761https://doaj.org/toc/2072-6643Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients that are undergoing chemotherapies. However, earlier research on the relationship between BMI and survival in patients taking epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) yielded contradictory results. These publications either had a limited number of patients or were getting TKIs in various lines of therapy, which might explain why the outcomes were contradictory. As a result, we undertook retrospective study to examine the effect of BMI on survival outcomes in patients with advanced EGFR mutant NSCLC receiving first-line EGFR-TKIs. We also compared the findings to those with wild-type EGFR. Between November 2010 and March 2014, 513 patients with advanced NSCLC were enrolled in the study. According to the adjusted BMI cut-off point for Asia, 35 out of 513 (6.8%) patients were underweight (BMI < 18.5 kg/m<sup>2</sup>), whereas 197 (38.4%) were overweight (BMI > 24 kg/m<sup>2</sup>). Overweight patients with wild-type EGFR exhibited longer progression-free survival (4.6 vs. 2.1 months, <i>p</i> = 0.003) and overall survival (OS) (8.9 vs. 4.3 months, <i>p</i> = 0.003) than underweight patients. Overweight patients with EGFR mutations had a longer OS than normal-weight patients (23.0 vs. 20.2 months, <i>p</i> = 0.025). Bodyweight reduction was related to a shorter OS in both the mutant EGFR patients (17.1 vs. 30.5 months, <i>p</i> < 0.001) and the wild-type EGFR patients (7.8 vs. 18.7 months, <i>p</i> < 0.001). In conclusion, advanced stages NSCLC patients with a lower BMI and early weight loss had a worse outcome that was independent of EGFR mutation status.Yu-Mu ChenChien-Hao LaiChiung-Yu LinYi-Hsuan TsaiYa-Chun ChangHung-Chen ChenChia-Cheng TsengHuang-Chih ChangKuo-Tung HuangYung-Che ChenWen-Feng FangChin-Chou WangTung-Ying ChaoMeng-Chih LinMDPI AGarticlebody mass indexweight lossnon-small cell lung cancertyrosine kinase inhibitorNutrition. Foods and food supplyTX341-641ENNutrients, Vol 13, Iss 3761, p 3761 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	body mass index weight loss non-small cell lung cancer tyrosine kinase inhibitor Nutrition. Foods and food supply TX341-641
spellingShingle	body mass index weight loss non-small cell lung cancer tyrosine kinase inhibitor Nutrition. Foods and food supply TX341-641 Yu-Mu Chen Chien-Hao Lai Chiung-Yu Lin Yi-Hsuan Tsai Ya-Chun Chang Hung-Chen Chen Chia-Cheng Tseng Huang-Chih Chang Kuo-Tung Huang Yung-Che Chen Wen-Feng Fang Chin-Chou Wang Tung-Ying Chao Meng-Chih Lin Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
description	Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients that are undergoing chemotherapies. However, earlier research on the relationship between BMI and survival in patients taking epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) yielded contradictory results. These publications either had a limited number of patients or were getting TKIs in various lines of therapy, which might explain why the outcomes were contradictory. As a result, we undertook retrospective study to examine the effect of BMI on survival outcomes in patients with advanced EGFR mutant NSCLC receiving first-line EGFR-TKIs. We also compared the findings to those with wild-type EGFR. Between November 2010 and March 2014, 513 patients with advanced NSCLC were enrolled in the study. According to the adjusted BMI cut-off point for Asia, 35 out of 513 (6.8%) patients were underweight (BMI < 18.5 kg/m<sup>2</sup>), whereas 197 (38.4%) were overweight (BMI > 24 kg/m<sup>2</sup>). Overweight patients with wild-type EGFR exhibited longer progression-free survival (4.6 vs. 2.1 months, <i>p</i> = 0.003) and overall survival (OS) (8.9 vs. 4.3 months, <i>p</i> = 0.003) than underweight patients. Overweight patients with EGFR mutations had a longer OS than normal-weight patients (23.0 vs. 20.2 months, <i>p</i> = 0.025). Bodyweight reduction was related to a shorter OS in both the mutant EGFR patients (17.1 vs. 30.5 months, <i>p</i> < 0.001) and the wild-type EGFR patients (7.8 vs. 18.7 months, <i>p</i> < 0.001). In conclusion, advanced stages NSCLC patients with a lower BMI and early weight loss had a worse outcome that was independent of EGFR mutation status.
format	article
author	Yu-Mu Chen Chien-Hao Lai Chiung-Yu Lin Yi-Hsuan Tsai Ya-Chun Chang Hung-Chen Chen Chia-Cheng Tseng Huang-Chih Chang Kuo-Tung Huang Yung-Che Chen Wen-Feng Fang Chin-Chou Wang Tung-Ying Chao Meng-Chih Lin
author_facet	Yu-Mu Chen Chien-Hao Lai Chiung-Yu Lin Yi-Hsuan Tsai Ya-Chun Chang Hung-Chen Chen Chia-Cheng Tseng Huang-Chih Chang Kuo-Tung Huang Yung-Che Chen Wen-Feng Fang Chin-Chou Wang Tung-Ying Chao Meng-Chih Lin
author_sort	Yu-Mu Chen
title	Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_short	Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_full	Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_fullStr	Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_full_unstemmed	Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
title_sort	body mass index, weight loss, and mortality risk in advanced-stage non-small cell lung cancer patients: a focus on egfr mutation
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f6b4a7988ca7414f8acc45de727e6885
work_keys_str_mv	AT yumuchen bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT chienhaolai bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT chiungyulin bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT yihsuantsai bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT yachunchang bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT hungchenchen bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT chiachengtseng bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT huangchihchang bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT kuotunghuang bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT yungchechen bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT wenfengfang bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT chinchouwang bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT tungyingchao bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation AT mengchihlin bodymassindexweightlossandmortalityriskinadvancedstagenonsmallcelllungcancerpatientsafocusonegfrmutation
_version_	1718410989784793088

Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation

Ejemplares similares